Myriad Genetics (MYGN) Gross Margin (2009 - 2026)

Myriad Genetics has disclosed Gross Margin across 18 years of filings, most recently posting 68.66% for Q1 2026.

• In Q1 2026, Gross Margin rose 16.0% year-over-year to 68.66%; the TTM figure through Mar 2026 stood at 69.96% (down 5.0% YoY), while the FY2025 annual figure was 69.93%, up 4.0% from the prior year.
• Gross Margin eased to 68.66% in Q1 2026, from 69.97% in the prior quarter.
• Over the last five years, Gross Margin for MYGN reached as high as 72.28% in Q2 2022 and fell as low as 33.24% in Q4 2022.
• The 5-year median for Gross Margin is 69.55% (2024), against an average of 65.85%.
• Annual changes were most pronounced in 2022 — Gross Margin plunged 14636 bps — and 2024, when it jumped 2994 bps.
• A 5-year view of Gross Margin shows it stood at 33.24% in 2022, then climbed by 25 bps to 41.71% in 2023, then soared by 72 bps to 71.65% in 2024, then decreased by 2 bps to 69.97% in 2025, then dropped by 2 bps to 68.66% in 2026.
• According to Business Quant data, Gross Margin over the past three periods registered 68.66%, 69.97%, and 69.91% for Q1 2026, Q4 2025, and Q3 2025 respectively.